WYNNEWOOD, Pa.--(BUSINESS WIRE)--CD Diagnostics, Inc. announced today that it will be featured in a segment of the Discovery Channel show, Health Heroes, airing on April 15, 2013 at 7:00 a.m. EDT and 7:00 a.m. PDT.
The show will focus on the latest advancements in health and wellness. The CD Diagnostics’ segment will highlight industry leaders discussing the impact of the company’s game-changing technology on the orthopaedic community. Other companies highlighted in the episode include Acteon North America, Covaris, and Photocure, Inc.
Richard Birkmeyer, CEO of CD Diagnostics, stated, “We are very excited about our feature on Health Heroes. We are pleased to shed light on joint infection, a serious condition that negatively affects joint replacement patients worldwide.”
“Health Heroes is really looking forward to educating the public on some of the innovative breakthroughs and advancements currently being made in the medical community," said Michele Nehls, Producer for the series.
About Health Heroes:
Health Heroes is a powerful TV series dedicated to defining and exploring today’s latest medical advances in all areas of health and wellness. Written with both the industry professional and television audience in mind, Health Heroes educates, entertains and enlightens the lives of our viewers.
About CD Diagnostics, Inc.:
CD Diagnostics is a fully integrated diagnostics company with expertise in immunoassay development and commercialization. The company combines expertise in immunoassay development with biomarker research, patented technology, and GMP manufacturing, to deliver a range of products that address challenging diagnostic issues. The company is improving patient outcomes by providing more accurate and rapid diagnosis. CD Diagnostics recently completed the acquisition of Citrano Medical Laboratories, a CLIA-certified laboratory that has provided comprehensive clinical testing services to its clients for 39 years. The CLIA laboratory and CD Diagnostics’ sample acquisition programs with major hospitals and medical research institutions help to facilitate the rapid development and commercialization of the company’s laboratory-developed tests (LDTs). The laboratory-developed test for peri-prosthetic joint infection, developed with Zimmer, was released in November 2012. Additional tests for other disease states and for use as companion diagnostics are being developed.
